

2nd Hepatitis C Technical Advisory Group (TAG) Meeting
Agenda
October 24, 2016

8:30-9:00	Registration	
9:00-9:15	Welcome and Opening Remarks	Dr. Davit Sergeenko , Minister of Labour, Health and Social Affairs (MoLHSA) Mr. Ian C. Kelly , US Ambassador in Georgia
9:15-9:45	Introduction of TAG Members and Role of the TAG <ul style="list-style-type: none"> • TAG objectives • Governance • 2015 TAG recommendations • Overview of agenda 	Dr. John Ward , TAG Chair, US CDC
9:45-10:00	Media Coverage	
10:00-10:15	Elimination <ul style="list-style-type: none"> • Global targets for HCV elimination 	Dr. Marc Bulterys , World Health Organization, Geneva, Switzerland
10:15-10:45	Overview and Progress of the HCV Elimination Program in Georgia	Mr. Valeri Kvaratskhelia , Deputy Minister of MoLHSA
10:45-11:00	Georgia HCV Epidemiology and Elimination Plan <ul style="list-style-type: none"> • Overview/serosurvey results • Elimination plan <ul style="list-style-type: none"> a. Development b. Sections c. Activities 	Dr. Amiran Gamkrelidze , National Center for Disease Control (NCDC)
11:00-11:15	Break	
11:15-11:25	Georgia HCV Elimination Program: Role of CDC and Partners	Dr. Juliette Morgan , US CDC
11:25-11:35	Overview of Monitoring and Evaluation (M & E)	Dr. James Emshoff , Georgia State University, USA
11:35-11:50	Modeling: What Will It Take to Achieve Hepatitis C Elimination in Georgia? <ul style="list-style-type: none"> • Based on first-year activities, will Georgia achieve elimination targets by 2020, 2025, or 2030? • Potential outcome and intervention targets 	Dr. Peter Vickerman , University of Bristol, UK
11:50-12:15	Discussion by TAG/Q & A	
12:15-1:15	Lunch in Parnas Café	
1:15-2:15 1:15-1:45 1:45-2:15	Elimination Plan: Improve HCV Laboratory Diagnostics <ul style="list-style-type: none"> • Current activities, gaps, proposed actions/priorities for 2017, and M & E indicators & targets • Core Antigen Study • Discussion by TAG/Q & A 	Dr. Giorgi Kamkamidze , Neolab Dr. Nazi Chitadze , Lugar Center, NCDC TAG discussant: Dr. Anders Widell , Lund University, Sweden

<p>2:15-3:15 2:15-2:45</p> <p>2:45-3:15</p>	<p>Elimination Plan: Identify Persons Infected With HCV</p> <ul style="list-style-type: none"> • Current activities, gaps, proposed actions/priorities for 2017, and M & E indicators & targets • Proposed screening recommendations • Evaluation of HCV screening programs • Discussion by TAG/Q & A 	<p>Dr. Maia Alkhazashvili, NCDC Dr. Davit Baliashvili, NCDC Dr. Muazzam Nasrullah, US CDC</p> <p>TAG discussant: Dr. Marc Bulterys, World Health Organization, Geneva, Switzerland</p>
<p>3:15-3:45</p>	<p>Break</p>	
<p>3:45-5:00 3:45-4:30</p> <p>4:30-5:00</p>	<p>Elimination Plan: Provide HCV Care and Treatment</p> <ul style="list-style-type: none"> • Current activities, gaps, and proposed actions/priorities for 2017, and M & E indicators & targets • Capacity building: ECHO in Georgia • Discussion by TAG/Q & A 	<p>Dr. Tengiz Tsertsvadze, IDACIRC, Georgia Dr. Sanjeev Arora, University of New Mexico, US</p> <p>TAG discussant: Dr. Yaman Tokat, Florence Hospital, Turkey & Dr. Sanjeev Arora, University of New Mexico, US</p>
<p>5:00-5:30 5:00-5:15</p> <p>5:15-5:30</p>	<p>Elimination Plan: Promote Advocacy, Awareness, and Education, and Partnerships for HCV-Associated Resource Mobilization</p> <ul style="list-style-type: none"> • Current activities, gaps, proposed actions/priorities for 2017, and M & E indicators & targets • Discussion by TAG/Q & A 	<p>Dr. Maia Shishniashvili, NCDC</p> <p>Discussant: Dr. Marina Topuridze, NCDC; TAG discussant: Dr. Tatjana Reic, European Liver Patients Association, Croatia</p>
<p>5:30-6:00</p>	<p>Summary of Day 1 and Closing Remarks</p>	<p>Dr. John Ward, TAG Chair, US CDC</p>
<p>6:30</p>	<p>Dinner at La Bohema</p>	

2nd Hepatitis C Technical Advisory Group (TAG) Meeting
Agenda
 October 25, 2016

9:00-9:15	Opening Remarks, Review Day 1	Dr. John Ward , TAG Chair, US CDC
9:15-10:45 9:15-9:30 9:30-10:00 10:00-10:15 10:15-10:45	<p>Elimination Plan: Prevent HCV Transmission Harm Reduction</p> <ul style="list-style-type: none"> Current activities, gaps, proposed actions/priorities for 2017, and M & E indicators & targets Discussion by TAG/Q & A <p>Blood Safety</p> <ul style="list-style-type: none"> Current activities, gaps, proposed actions/priorities for 2017, and M & E indicators & targets Discussion by TAG/Q & A 	<p>Mr. Paata Sabelashvili</p> <p>Discussants: Dr. Ketevan Stvilia, Global Fund & Dr. Khatuna Kutateladze, Georgia Harm Reduction Network; TAG discussant: Dr. Niklas Luhmann, Médecins du Monde, France</p> <p>Dr. Eter Kipiani, NCDC</p> <p>Discussants: Dr. Eka Kavtaradze, NCDC; Dr. Babilina Turkia, MoLHSA; TAG discussant: Dr. Sheila Marie Keating, Blood Systems Research Institute, US</p>
10:45-11:00	Break	
11:00-12:00 11:00-11:15 11:15-11:25 11:25-12:00	<p>Elimination Plan: Prevent HCV Transmission (cont.) Infection Control in Healthcare, Non-traditional Healthcare and Other Community Settings</p> <ul style="list-style-type: none"> Current activities, gaps, proposed actions/priorities for 2017, and M & E indicators & targets IPC National Guidelines: CDC-sponsored cross-cutting support Discussion by TAG/Q & A 	<p>Dr. Giorgi Chakhunashvili, NCDC Dr. Juliette Morgan, US CDC</p> <p>TAG discussant: Dr. Margaret Hellard, Burnet Institute, Australia</p>
12:00-12:45 12:00-12:15 12:15-12:45	<p>Elimination Plan: Improve HCV Surveillance</p> <ul style="list-style-type: none"> Current activities, gaps, proposed actions/priorities for 2017, and M & E indicators & targets Discussion by TAG/Q & A 	<p>Dr. Maia Butsashvili, Health Research Union</p> <p>Discussants: Dr. Khatuna Zakhashvili, NCDC & Dr. Maia Tsereteli, NCDC; TAG discussant: Dr. Ken Nelson, Johns Hopkins University, US</p>
12:45-1:30 12:45-1:00 1:00-1:30	<p>Research</p> <ul style="list-style-type: none"> Proposed research activities, and priorities for 2017 Discussion/Q & A 	<p>Dr. Amiran Gamkrelidze, NCDC Dr. Francisco Averhoff, US CDC TAG discussant: All</p>

1:30-3:30	Lunch for All in Parnas Café TAG Members Lunch	
3:30-5:15	<p>TAG Recommendations and 2017 Priorities (5-minute presentations followed by 10 minutes of discussion for each section)</p> <ul style="list-style-type: none"> • Improve HCV laboratory diagnostics • Identify persons infected with HCV • Provide HCV care and treatment • Promote advocacy, awareness, and education, and partnerships for HCV-associated resource mobilization • Prevent HCV transmission <ul style="list-style-type: none"> • Harm reduction • Blood safety • Infection control in healthcare, non-traditional healthcare, and other community settings • Improve HCV surveillance 	Dr. John Ward , TAG Chair, US CDC & TAG members
5:15-5:30	Closing Remarks	